Atara Biotherapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
ATRA$7.87-1.1%Stored close · as of Nov 6, 2026
Contents
Item 1. Condensed Consolidated Balance Sheets
Condensed Conso lidated Balance Sheets
(In thousands, except per share amounts)
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $13,841 | $25,030 |
| Short-term investments | — | 17,466 |
| Restricted cash | 146 | 146 |
| Accounts receivable | 8,875 | 1,482 |
| Inventories | — | 10,655 |
| Other current assets | 4,320 | 10,115 |
| Total current assets | 27,182 | 64,894 |
| Property and equipment, net | 285 | 1,294 |
| Operating lease assets | 31,727 | 39,807 |
| Other assets | 2,844 | 3,103 |
| Total assets | $62,038 | $109,098 |
| Liabilities and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $1,384 | $4,367 |
| Accrued compensation | 4,599 | 6,589 |
| Accrued research and development expenses | 1,783 | 7,984 |
| Deferred revenue | 15,983 | 95,092 |
| Other current liabilities | 24,143 | 20,542 |
| Total current liabilities | 47,892 | 134,574 |
| Deferred revenue – long-term | — | — |
| Operating lease liabilities – long-term | 26,708 | 29,914 |
| Liability related to the sale of future revenues – long-term | 39,383 | 38,624 |
| Other long-term liabilities | 3,127 | 3,269 |
| Total liabilities | 117,110 | 206,381 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity (deficit): | ||
| Common stock—$0.0001 par value, 500,000 shares authorized as of March 31, 2025 and December 31, 2024; 5,924 and 5,859 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 1 | 1 |
| Additional paid-in capital | 1,961,470 | 1,957,261 |
| Accumulated other comprehensive (loss) income | — | 8 |
| Accumulated deficit | (2,016,543) | (2,054,553) |
| Total stockholders’ equity (deficit) | (55,072) | (97,283) |
| Total liabilities and stockholders’ equity (deficit) | $62,038 | $109,098 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.